Bambusa Therapeutics

We are a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life. Our vision is to deliver transformative medicines for I&I patients across every stage of disease. We use third-party, advanced antibody engineering to create long-acting bispecific antibodies that combine clinically and commercially validated biologic pathways into a single molecule formulated for high-concentration subcutaneous (“SubQ”) delivery. Since our inception on March 14, 2024 (“Inception”), we have acquired assets from BioNTech Pharmaceuticals R&Dthat became our lead product candidates, BBT001 and BBT002, secured regulatory clearances to initiate clinical trials for these product candidates across multiple geographical regions, advanced them from preclinical to clinical development, completed dosing and safety follow ups of intravenous (“IV”) formulations of these product candidates in healthy volunteers, initiated enrollment and dosing of patients for proof-of-concept (“PoC”) readouts, developed high concentration SubQ formulations of both product candidates, initiated healthy volunteer and PoC substudies of such SubQ formulations, and initiated SubQ dosing of BBT001 in patients.